Mylan Adds Topical Pharmaceuticals Business

Mylan NV (NASDAQ: MYL) still has money to spend, following its $9.9 billion deal for Swedish drug maker Meda AB in February. On Friday, May 13, RoundTable Healthcare Partners announced that its portfolio company, Renaissance Acquisition Holdings, LLC, had agreed to sell its non-sterile topical drug business to Mylan for $950 million, plus additional contingent payments of up to $50 million.

The topical division is a specialty pharmaceutical business focused on manufacturing, developing, sales and marketing of branded and generic drug products. The acquisition brings a complementary portfolio of approximately 25 branded and generic topical products, an active pipeline of approximately 25 products, and an established U.S. sales and marketing infrastructure targeting dermatologists.

Renaissance Acquisition will continue to own and operate its sterile-focused specialty drug business.



Leave a Reply

Your email address will not be published. Required fields are marked *